KYMR
Kymera Therapeutics Inc

805
Mkt Cap
$6.93B
Volume
1.86M
52W High
$103.00
52W Low
$19.45
PE Ratio
-24.94
KYMR Fundamentals
Price
$89.68
Prev Close
$87.81
Open
$90.09
50D MA
$64.54
Beta
1.66
Avg. Volume
754,941.89
EPS (Annual)
-$2.98
P/B
6.80
Rev/Employee
$250,382.98
Loading...
Loading...
News
all
press releases
BVF Inc. IL Boosts Stake in Kymera Therapeutics, Inc. $KYMR
BVF Inc. IL raised its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 6.6% in the second quarter, according to the company in its most recent filing with the...
MarketBeat·2h ago
News Placeholder
More News
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Director Buys $172,499,918.00 in Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bros. Advisors Lp Baker acquired 2,005,813 shares of the business's stock in a transaction that occurred on Thursday, December 11th...
MarketBeat·13h ago
News Placeholder
Kymera's Eczema Drug Gets Fast Track Designation in the United States
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
Zacks·20h ago
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Director Bros. Advisors Lp Baker Acquires 2,005,813 Shares
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bros. Advisors Lp Baker purchased 2,005,813 shares of the stock in a transaction dated Thursday, December 11th. The stock was...
MarketBeat·22h ago
News Placeholder
Redmile Group LLC Trims Stock Holdings in Kymera Therapeutics, Inc. $KYMR
Redmile Group LLC cut its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 18.3% during the second quarter, according to the company in its most recent disclosure with...
MarketBeat·23h ago
News Placeholder
Frontier Capital Management Co. LLC Grows Holdings in Kymera Therapeutics, Inc. $KYMR
Frontier Capital Management Co. LLC grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 272.7% during the 2nd quarter, according to the company in its most recent 13F...
MarketBeat·1d ago
News Placeholder
HC Wainwright Has Positive Estimate for KYMR FY2029 Earnings
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - HC Wainwright increased their FY2029 earnings estimates for shares of Kymera Therapeutics in a report released on Tuesday, December 9th. HC...
MarketBeat·2d ago
News Placeholder
Norges Bank Invests $1.81 Million in Kymera Therapeutics, Inc. $KYMR
Norges Bank bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission...
MarketBeat·2d ago
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $125.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co. boosted their price objective on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the stock an "overweight" rating in a research report on Wednesday...
MarketBeat·3d ago
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up After Analyst Upgrade
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Analyst Upgrade...
MarketBeat·3d ago

Latest KYMR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.